The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Interview series: Part 1 of 5 - Rethinking site activation to cut startup timelines
How contract standardisation, proactive budget alignment, and AI-enabled negotiation tools can reduce site activation delays and turn agreements into strategic accelerators.
-
Interview series: Part 2 of 5 - Closing communication gaps during study startup
Why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how bidirectional, site-informed engagement models can improve collaboration and momentum.
-
Interview series: Part 3 of 5 - Applying AI to reduce administrative burden without losing the human touch
How practical AI applications can streamline contracts and startup workflows while preserving the central role of investigators, site staff, and patient relationships.
-
Interview series: part 4 of 5 - Why startup timelines are worsening – and how to reduce the trend
The operational pressures driving longer activation timelines, from protocol complexity to site competition, and how earlier, more flexible site engagement can restore momentum.
-
Interview series: Part 5 of 5 - Centering site experience to accelerate site activation
How sponsor and CRO practices that prioritise site needs, clarity, and partnership can strengthen trust, sustain momentum, and speed activation.
-
Examining the growing delays in clinical trial start-up
Brian Mallon discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
-
New ICON survey shows sites face growing delays and communication gaps during study startup
ICON’s survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and insufficient collaboration from sponsors and CROs.
-
Smarter starts, stronger trials: How data is driving faster site activation
Feasibility, site selection and study startup are among the most complex areas of clinical development, yet they remain stubbornly inefficient. ICON’s Brian Mallon explores how sponsors and CROs are leveraging AI, predictive analytics and integrated data environments for faster, more predictable trial delivery and stronger site partnerships. Read the full article.
-
Talking the talk
At ICON ensuring scientifically representative participation is not a stand-alone initiative, it’s embedded into every trial we support, shaping smarter, faster, higher-quality research. We start with the patient’s voice.
-
ICON discusses how AI is changing clinical trial recruitment and diversity
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
